

**Staphylococcus haemolyticus, Strain NRS115**

**Catalog No. NR-45921**

**Product Description:** *Staphylococcus haemolyticus* (*S. haemolyticus*), strain NRS115 was isolated in February 2002 from a 45-year-old male inpatient in California, USA. Strain NRS115 is a co-isolate with *S. haemolyticus*, strain NRS116 from the same patient. *S. haemolyticus*, strain NRS115 is reported to be a vancomycin-intermediate *S. haemolyticus* strain.

**Lot<sup>1</sup>: 70011778**

**Manufacturing Date: 24JAN2018**

TEST	SPECIFICATIONS	RESULTS
<b>Phenotypic Analysis</b> Cellular morphology Colony morphology <sup>2</sup>  Motility (wet mount) Hemolysis <sup>2</sup> Biochemical characterization Catalase Coagulase <sup>3</sup> VITEK <sup>®</sup> 2 Compact (GP card)	Gram-positive cocci Report results  Report results Report results  Positive Negative <i>S. haemolyticus</i> (≥ 89%)	Gram-positive cocci Circular, low convex, entire, smooth, opaque and white (Figure 1) Non-motile Non-hemolytic  Positive Negative <i>S. haemolyticus</i> (99%)
<b>Antibiotic Susceptibility Profile<sup>4</sup></b> VITEK <sup>®</sup> (AST-GP71 card) Beta-lactamase <sup>5</sup> Cefoxitin screen Benzylpenicillin Oxacillin Gentamicin Ciprofloxacin Levofloxacin Moxifloxacin Clindamycin (inducible resistance) Erythromycin Clindamycin Quinupristin/dalfopristin Linezolid Daptomycin Vancomycin Minocycline Tetracycline Tigecycline Nitrofurantoin Rifampicin Trimethoprim/sulfamethoxazole Estest <sup>®</sup> antibiotic test strips <sup>7</sup> Teicoplanin Vancomycin	Report results Report results Report results Resistant Sensitive Resistant Report results Report results Report results Resistant Sensitive Sensitive Sensitive Susceptible Report results Report results Report results Report results Report results Report results Report results Resistant  Report results Sensitive	Positive Positive Resistant (≥ 0.5 µg/mL) Resistant (≥ 1 µg/mL) Sensitive (= 4 µg/mL) Resistant (≥ 8 µg/mL) Resistant (= 4 µg/mL) Intermediate (= 1 µg/mL) Negative Resistant (≥ 8 µg/mL) Sensitive (= 0.25 µg/mL) Sensitive (= 0.5 µg/mL) Sensitive (≤ 4 µg/mL) Susceptible (≤ 0.12 µg/mL) Sensitive (= 1 µg/mL) Sensitive (= 2 µg/mL) Resistant (≥ 16 µg/mL) Resistant (= 1 µg/mL) <sup>6</sup> Sensitive (≤ 16 µg/mL) Sensitive (≤ 0.5 µg/mL) Resistant (≥ 320 µg/mL)  Sensitive (= 6 to 8 µg/mL) <sup>8</sup> Sensitive (= 2 µg/mL)
<b>Genotypic Analysis</b> Sequencing of 16S ribosomal RNA gene (~ 720 base pairs)	≥ 99% sequence identity to <i>S. haemolyticus</i> , type strain (GenBank: KT989857.1)	99.7% sequence identity to <i>S. haemolyticus</i> , type strain (GenBank: KT989857.1) <sup>9</sup>
<b>Purity (post-freeze)<sup>10</sup></b>	Consistent with expected colony morphology	Consistent with expected colony morphology
<b>Viability (post-freeze)<sup>2</sup></b>	Growth	Growth

<sup>1</sup>*S. haemolyticus*, strain NRS115 was deposited to BEI Resources as part of the NARSA collection. NR-45921 was produced by inoculation of the deposited material into Tryptic Soy broth and grown 1 day at 37°C in an aerobic atmosphere. Broth inoculum was added to Tryptic Soy agar with 5% defibrinated sheep blood kolles which were grown 1 day at 37°C in an aerobic atmosphere to produce this lot.

<sup>2</sup>1 day at 37°C in an aerobic atmosphere on Tryptic Soy agar with 5% defibrinated sheep blood

<sup>3</sup>1 day at 37°C in rabbit serum with 0.15% EDTA (Coagulase Plasma BBL™ 240827)

<sup>4</sup>Minimum Inhibitory Concentration (MIC); MIC Interpretation Guideline: CLSI M100-S22 (2012)

<sup>5</sup>The production of beta-lactamase was detected using a Cefinase™ Paper Disc (BBL™ 231650).

<sup>6</sup>MIC Interpretation Guideline: EUCAST Version 4.0 (2014)

<sup>7</sup>1 day at 37°C in an aerobic atmosphere on Mueller Hinton agar

<sup>8</sup>*S. haemolyticus*, strain NRS115 was deposited as resistant to teicoplanin. Antibiotic susceptibility testing using bioMérieux Etest® antibiotic test strips and performed in duplicate determined that strain NRS115 is sensitive to teicoplanin. For additional information on susceptibility testing of glycopeptide intermediate *S. aureus* (GISA) strains, please refer to Walsh, T. R., et al. "Evaluation of Current Methods for Detection of Staphylococci with Reduced Susceptibility to Glycopeptides." *J. Clin. Microbiol.* 39 (2001): 2439-2444. PubMed: 11427551.

<sup>9</sup>Also consistent with other *Staphylococcus* species

<sup>10</sup>Purity of this lot was assessed for 8 days at 37°C in an aerobic atmosphere with 5% CO<sub>2</sub> on Tryptic Soy agar with 5% defibrinated sheep blood.

**Figure 1: Colony Morphology**



/Heather Couch/  
Heather Couch

12 JUL 2018

Program Manager or designee, ATCC Federal Solutions

ATCC®, on behalf of BEI Resources, hereby represents and warrants that the material provided under this certificate has been subjected to the tests and procedures specified and that the results described, along with any other data provided in this certificate, are true and accurate to the best of ATCC®'s knowledge.

ATCC® is a trademark of the American Type Culture Collection.

You are authorized to use this product for research use only. It is not intended for human use.

